Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes
Stefano Ciardullo, Gianluca Perseghin
Metabolism (2021) Vol. 121, pp. 154752-154752
Closed Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

NAFLD: Mechanisms, Treatments, and Biomarkers
Fatiha Nassir
Biomolecules (2022) Vol. 12, Iss. 6, pp. 824-824
Open Access | Times Cited: 250
Association between SII and hepatic steatosis and liver fibrosis: A population-based study
Ruijie Xie, Mengde Xiao, Lihong Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 149
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
Dan‐Qin Sun, Giovanni Targher, Christopher D. Byrne, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 3, pp. 386-403
Open Access | Times Cited: 57
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
Zobair M. Younossi, Linda Henry
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 9-19
Open Access | Times Cited: 19
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease
Xiaodong Zhou, Seung Up Kim, Terry Cheuk‐Fung Yip, et al.
Gut (2024) Vol. 73, Iss. 11, pp. 1883-1892
Closed Access | Times Cited: 19
Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
J Bernhard, L Galli, Walter S. Speidl, et al.
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Open Access | Times Cited: 2
Relationship Between Non-Alcoholic Fatty Liver Disease and Degree of Hepatic Steatosis and Bone Mineral Density
Ruijie Xie, Mingjiang Liu
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 68
Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study
Ibrahim Ayada, Laurens A. van Kleef, Huai Zhang, et al.
EBioMedicine (2022) Vol. 87, pp. 104392-104392
Open Access | Times Cited: 62
Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
Yongin Cho, Hyungjin Rhee, Young‐Eun Kim, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 54
Prognostic nutritional index as a risk factor for diabetic kidney disease and mortality in patients with type 2 diabetes mellitus
Junlin Zhang, Yao Chen, Liang Zou, et al.
Acta Diabetologica (2022) Vol. 60, Iss. 2, pp. 235-245
Open Access | Times Cited: 40
Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy?
Amirhossein Sahebkar, Zahra Foroutan, Niki Katsiki, et al.
Metabolism (2023) Vol. 146, pp. 155659-155659
Closed Access | Times Cited: 32
Association between the platelet/high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease: results from NHANES 2017–2020
Chunfeng Lu, Xiaomin Cang, Wangshu Liu, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 26
Associations between the platelet/high-density lipoprotein cholesterol ratio and likelihood of nephrolithiasis: a cross-sectional analysis in United States adults
Junjie Ni, Lin Lv, Pu Wu, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 15
A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
Shiqin Zhang, Xiaoling Ren, Bingzheng Zhang, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1859-1859
Open Access | Times Cited: 12
Elevated ALT/AST ratio as a marker for NAFLD risk and severity: insights from a cross-sectional analysis in the United States
Yanyan Xuan, Dingting Wu, Qin Zhang, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 9
Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China: A cross-sectional study
Yajun He, Nanfang Yao, Feng Tian, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 3, pp. 102973-102973
Closed Access | Times Cited: 8
Factors Associated with Advanced Liver Fibrosis in a Population with Type 2 Diabetes: A Multicentric Study in Mexico City.
Froylan David Martínez‐Sánchez, Maria Juliana Corredor-Nassar, Sandra Milena Feria-Agudelo, et al.
Journal of Clinical and Experimental Hepatology (2025) Vol. 15, Iss. 4, pp. 102536-102536
Open Access | Times Cited: 1
Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis
Kaneez Fatima, Abdul Moeed, Eisha Waqar, et al.
Clinics and Research in Hepatology and Gastroenterology (2021) Vol. 46, Iss. 4, pp. 101816-101816
Closed Access | Times Cited: 41
Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis
Stefano Ciardullo, Gianluca Perseghin
Diabetes Research and Clinical Practice (2022) Vol. 190, pp. 109981-109981
Closed Access | Times Cited: 34
Association of serum uric acid-to-high-density lipoprotein cholesterol ratio with non-alcoholic fatty liver disease in American adults: a population-based analysis
Yilian Xie, Kai Huang, Xiangyu Zhang, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 20
Low 25 (OH) vitamin D levels are associated with increased prevalence of nonalcoholic fatty liver disease and significant liver fibrosis
Stefano Ciardullo, Emanuele Muraca, Rosa Cannistraci, et al.
Diabetes/Metabolism Research and Reviews (2023) Vol. 39, Iss. 5
Open Access | Times Cited: 16
From liver to hormones: The endocrine consequences of cirrhosis
Juan Eduardo Quiroz‐Aldave, Elman Rolando Gamarra‐Osorio, María del Carmen Durand‐Vásquez, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 9, pp. 1073-1095
Open Access | Times Cited: 7
Examining the cross-sectional relationship of platelet/high-density lipoprotein cholesterol ratio with depressive symptoms in adults in the United States
Junjie Ni, Pu Wu, L. Xiaofeng, et al.
BMC Psychiatry (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Association between neutrophil-to-high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in the US population: a nationally representative cross-sectional study using NHANES data from 2017 to 2020
Yangni Lu, Xianli Xu, Jian‐Lin Wu, et al.
BMC Gastroenterology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Comparative Effectiveness and Safety of Atorvastatin Versus Rosuvastatin
Shiyu Zhou, Ruixuan Chen, Jiao Liu, et al.
Annals of Internal Medicine (2024)
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top